1. Home
  2. VERU vs SWZ Comparison

VERU vs SWZ Comparison

Compare VERU & SWZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VERU
  • SWZ
  • Stock Information
  • Founded
  • VERU 1971
  • SWZ 1986
  • Country
  • VERU United States
  • SWZ United States
  • Employees
  • VERU N/A
  • SWZ N/A
  • Industry
  • VERU Biotechnology: Pharmaceutical Preparations
  • SWZ Finance Companies
  • Sector
  • VERU Health Care
  • SWZ Finance
  • Exchange
  • VERU Nasdaq
  • SWZ Nasdaq
  • Market Cap
  • VERU 108.8M
  • SWZ 112.9M
  • IPO Year
  • VERU 1990
  • SWZ N/A
  • Fundamental
  • Price
  • VERU $0.57
  • SWZ $8.93
  • Analyst Decision
  • VERU Strong Buy
  • SWZ
  • Analyst Count
  • VERU 4
  • SWZ 0
  • Target Price
  • VERU $4.00
  • SWZ N/A
  • AVG Volume (30 Days)
  • VERU 6.2M
  • SWZ 14.2K
  • Earning Date
  • VERU 02-13-2025
  • SWZ 01-01-0001
  • Dividend Yield
  • VERU N/A
  • SWZ 6.59%
  • EPS Growth
  • VERU N/A
  • SWZ N/A
  • EPS
  • VERU N/A
  • SWZ N/A
  • Revenue
  • VERU $16,886,419.00
  • SWZ N/A
  • Revenue This Year
  • VERU N/A
  • SWZ N/A
  • Revenue Next Year
  • VERU N/A
  • SWZ N/A
  • P/E Ratio
  • VERU N/A
  • SWZ N/A
  • Revenue Growth
  • VERU 22.46
  • SWZ N/A
  • 52 Week Low
  • VERU $0.49
  • SWZ $7.12
  • 52 Week High
  • VERU $1.92
  • SWZ $8.57
  • Technical
  • Relative Strength Index (RSI)
  • VERU 44.48
  • SWZ 71.86
  • Support Level
  • VERU $0.49
  • SWZ $8.78
  • Resistance Level
  • VERU $0.56
  • SWZ $8.91
  • Average True Range (ATR)
  • VERU 0.05
  • SWZ 0.07
  • MACD
  • VERU 0.00
  • SWZ -0.01
  • Stochastic Oscillator
  • VERU 63.62
  • SWZ 89.19

About VERU Veru Inc.

Veru Inc is a biopharmaceutical company with a drug development program for the treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). The company is also in the late-stage development of certain drugs for the management of breast and prostate cancers. It also has a sexual health program that includes two products, ENTADFI, for the treatment of benign prostatic hyperplasia (BPH) and the FC2 Female Condom (Internal Condom). The company operates in a single segment and generates revenue from the USA which is the key revenue generating market, Brazil, and other regions.

About SWZ Swiss Helvetia Fund Inc. (The)

Swiss Helvetia Fund Inc is a non-diversified, closed-end investment company. Its investment objective is to seek long-term capital appreciation through investment in equity and equity-linked securities of Swiss companies. The group invests in various sectors such as pharmaceuticals, food and beverage, industrial goods and services, banks, personal and household goods, construction and materials, biotechnology, medical equipment, chemicals, technology, financial services, insurance, and retail.

Share on Social Networks: